WO2020205034A1 - Sialidase-resistant saccharide and method of making and using the same - Google Patents

Sialidase-resistant saccharide and method of making and using the same Download PDF

Info

Publication number
WO2020205034A1
WO2020205034A1 PCT/US2020/014608 US2020014608W WO2020205034A1 WO 2020205034 A1 WO2020205034 A1 WO 2020205034A1 US 2020014608 W US2020014608 W US 2020014608W WO 2020205034 A1 WO2020205034 A1 WO 2020205034A1
Authority
WO
WIPO (PCT)
Prior art keywords
sialic acid
fluoro
mmol
equiv
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/014608
Other languages
English (en)
French (fr)
Inventor
Chi-Huey Wong
Hong-Jay LO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP20783332.8A priority Critical patent/EP3947406A4/en
Priority to IL286492A priority patent/IL286492B1/en
Priority to KR1020267002768A priority patent/KR20260018203A/ko
Priority to KR1020217031324A priority patent/KR102920761B1/ko
Priority to CN202080022413.3A priority patent/CN115605491B/zh
Priority to CA3131096A priority patent/CA3131096A1/en
Application filed by Academia Sinica filed Critical Academia Sinica
Priority to US17/598,064 priority patent/US12384811B2/en
Priority to JP2021558537A priority patent/JP7621270B2/ja
Publication of WO2020205034A1 publication Critical patent/WO2020205034A1/en
Anticipated expiration legal-status Critical
Priority to JP2025005021A priority patent/JP2025063181A/ja
Priority to US19/267,282 priority patent/US20260008803A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • Sialic acid is a negatively charged monosaccharide often displayed at the outmost end of glycans on glycolipids and glycoproteins, which are involved in many physiological intra- and intercellular processes, including interactions with other biomolecules and receptors on cells, viruses, and bacteria. 1
  • sialylation plays an important role in regulating the function and fate of secreted glycoproteins and membrane-bound receptors. For example, sialylation of the epidermal growth factor receptor (EGFR) was shown to inhibit EGFR dimerization, thus interfering with EGF binding and phosphorylation, which is associated with tumorgenesis.
  • EGFR epidermal growth factor receptor
  • sialylation modulates the half-life of glycoproteins in blood circulation as desialylation of N-glycans exposes the underlining galactose, which is recognized by the hepatic asialoglycoprotein receptors leading to a rapid removal of the glycoprotein from circulation. 3 Hence, increasing the degree of sialylation could improve the half-life and undesirable effects of glycoprotein therapeutics.
  • Sialic acid derivatives with fluorine at the C-3 position are known to inhibit sialyltransferases and sialidases (or neuraminidases) and are more stable. 7
  • glycosylation with fluorinated sugars as donors often present a major challenge due to the strong electronic effect of the fluorine group that inactivates glycosylation reaction.
  • An aspect of the present invention is a method of preparing a saccharide that contains a 3-fluoro-sialic acid.
  • the method includes conducting a glycosylation reaction by reacting a 3-hydroxy-sialic acid with a saccharide to form an a2,6-linked 3-hydroxy-sialoside and conducting a fluorination reaction by reacting the a2,6-linked 3-hydroxy-sialoside with a fluorinating agent to form a saccharide containing a 3-fluoro-sialic acid.
  • Another aspect of this invention is a method of preparing a homogeneous antibody bonded to a saccharide that contains a 3-fluoro-sialic acid. The method is carried out by glycosylating a monoclonal antibody with the saccharide.
  • R 1 is Ac or H
  • R 2 is Bz or H
  • R 3 is methyl or H
  • R 4 is Bn or H
  • X is OH, a leaving group, or a saccharide.
  • “Ac” represents acetyl
  • “Bz” represents benzoyl
  • “Bn” represents benzyl
  • the saccharide can be a monosaccharide, a disaccharide, or an oligosaccharide.
  • a monoclonal antibody bonded to an a2,6-linked 3-fluoro-sialoside terminated N-glycan is also within the scope of the present invention.
  • the method includes administering to a subject in need thereof an effective amount of a monoclonal antibody bonded to an a2,6-linked 3-fluoro-sialoside terminated N-glycan.
  • FIG.1A shows two graphs depicting enzyme-catalyzed hydrolysis of three sialosides, i.e., 1, 2, and S27, as a function of enzyme concentration; and FIG.1B shows two graphs depicting sialidase inhibition as a function of the concentration of 2, S27, or 2-deoxy-2,3- didehydro-N-acetylneuraminic acid (DANA), a sialidase inhibitor.
  • FIG.2 is a stained electrophoresis gel of four N-glycans: (1) rituxan-G, (2) rituxan- F ax -SCT, (3) rituxan-SCT, and (4) commercial rituxan.
  • FIG.3 shows mass spectra obtained for three N-glycans , i.e., rituxan-F ax -SCT, rituxan-SCT, and rituxan.
  • Disclosed first in detail herein is a method of preparing a saccharide that contains a 3- fluoro-sialic acid.
  • the method includes the steps of conducting a glycosylation reaction by reacting a 3-hydroxy-sialic acid with a saccharide to form an a2,6-linked 3-hydroxy-sialoside and conducting a fluorination reaction by reacting the a2,6-linked 3-hydroxy-sialoside with a fluorinating agent to form a saccharide containing a 3-fluoro-sialic acid.
  • the saccharide can be a monosaccharide, a disaccharide, or an oligosaccharide. In an exemplary method, the saccharide is a monosaccharide.
  • the 3-hydroxy-sialic acid is a 2-bromo-3- hydroxy-sialic acid
  • the glycosylation reaction is conducted in the presence of silver trifluoromethanesulfonate (AgOTf) and disodium phosphate (Na 2 HPO 4 ).
  • AgOTf silver trifluoromethanesulfonate
  • Na 2 HPO 4 disodium phosphate
  • the glycosylation reaction is conducted in toluene.
  • the fluorinating agent is perfluoro-1- butanesulfonyl fluoride (NfF), and the fluorination reaction is conducted in the presence of a catalyst.
  • the catalyst is 1,8-diazabicyclo[5,4,0]-undec-7-ene (DBU).
  • the fluorination reaction is conducted in toluene.
  • this reaction can be conducted further in the presence of tris(dimethylamino)sulfonium difluorotrimethylsilicate (TASF).
  • TASF tris(dimethylamino)sulfonium difluorotrimethylsilicate
  • the 3-hydroxy-sialic acid is of formula (I):
  • the saccharide is a compound of formula (II):
  • the a2,6-linked 3-hydroxy-sialoside is a compound of formula (III):
  • the saccharide containing a 3-fluoro-sialic acid is a compound of formula (IV):
  • the method further includes conducting another glycosylation reaction by reacting the saccharide containing a 3-fluoro-sialic acid with a second saccharide.
  • Also within the scope of this invention is a method of preparing a homogeneous antibody bonded to a saccharide containing a 3-fluoro-sialic acid. Again, this method includes glycosylating a monoclonal antibody with a saccharide containing a 3-fluoro-sialic acid.
  • the saccharide containing a 3-fluoro-sialic acid is obtained by the method, and embodiments thereof, described above, which includes the steps of conducting a glycosylation reaction by reacting a 3-hydroxy-sialic acid with a saccharide to form an a2,6-linked 3-hydroxy-sialoside and conducting a fluorination reaction by reacting the a2,6-linked 3-hydroxy-sialoside with a fluorinating agent to form a saccharide containing a 3-fluoro-sialic acid.
  • the saccharide containing a 3-fluoro-sialic acid is an a2,6- linked 3-fluoro-sialoside terminated N-glycan, which can be of formula (V):
  • R 1 , R 2 , R 3 , R 4 , and X are defined in the SUMMARY section above.
  • the compound is of formula (IV):
  • the compounds of formula (VI) each includes X being an N-glycan.
  • An exemplary compound of this embodiment is of formula (V):
  • the present invention also covers a monoclonal antibody bonded to a saccharide containing a 3-fluoro-sialic acid, the saccharide containing a 3-fluoro-sialic acid being an a2,6-linked 3-fluoro-sialoside terminated N-glycan.
  • the a2,6-linked 3-fluoro- sialoside terminated N-glycan is of formula (V) shown above.
  • the cancer can be leukemia or lymphoma
  • the autoimmune disease can be rheumatoid arthritis, autoimmune hemolytic anemia, pure red cell aplasia, thrombotic thrombocytopenic purpura, idiopathic
  • thrombocytopenic purpura leukemia lymphoma, Evans syndrome, vasculitis, bullous skin disorders, type 1 diabetes mellitus, Sjogren’s syndrome, anti-NMDA receptor encephalitis, Devic’s disease, Graves’ ophthalmopathy, autoimmune pancreatitis, opsoclonus myoclonus syndrome, or a IgG4-related disease.
  • treating refers to administering a pharmaceutical composition described above to a subject, who has an above-described disease, i.e., cancer, a symptom of such a disease, or a predisposition toward such a disease, with the purpose of conferring a therapeutic or prophylactic effect.
  • an effective amount refers to the amount of an active drug that is required to confer such effect. Effective doses will vary, as recognized by those skilled in the art, depending on the types of disease treated, route of administration, excipient usage, and the possibility of co-usage with other therapeutic treatment.
  • 3-fluoro-substitued sialic acid derivatives compared to non-fluorinated sialic acid derivatives, are known to be more stable towards sialidases. 7
  • DFSA 2,3-difluorosialic acid
  • hexasaccharide 14 which is a precursor of 17 (Scheme 6).
  • homogeneous 3F ax -Neu5Ac-glycoform to FcgRIIIa was measured by surface plasma resonance analysis 6 together with the parent nonfluorinated glycoform (G2S2) and a commercial sample of rituximab (major glycoforms: G1F1, G0F1, G2F1).
  • G2S2 nonfluorinated glycoform
  • rituximab major glycoforms: G1F1, G0F1, G2F1
  • the homogeneous glycoforms of IgG bearing biantennary N-glycans with a2,6-sialaylation and without core fucose demonstrated 39.9-fold (Neu5Ac-G2S2) and 37.4-fold (3F ax -Neu5Ac-G2S2) improvement in binding avidity (see Table 4).
  • glycoproteins glycoproteins
  • High-resolution mass spectra were recorded on an Agilent LC/MSD TOF mass spectrometer by electrospray ionization time-of-flight (ESI-TOF) reflectron experiments.
  • HPLC measurements were performed on a Hitachi HPLC D-7000 system.
  • RRV measurements were recorded using a normal-phase ZORBAX RX-SIL, 5 ⁇ m, 4.6 x 250mm (Colloidal Silica, Agilent Technologies) using the solvent system EtOAc/hexane with 1 mL/min flow rate, and visualized at 254 nm.
  • reaction mixture was cooled to -50 °C and dry Na2HPO4 (1.07 g, 7.54 mmol, 4.2 equiv.) was added, followed by AgOTf (692 mg, 2.69 mmol, 1.5 equiv., in toluene 18 mL) with stirring.
  • AgOTf 692 mg, 2.69 mmol, 1.5 equiv., in toluene 18 mL
  • the reaction mixture was diluted with EtOAc (80 mL), washed with 20% aq. Na2S2O3 (10 mL), satd. aq. NaHCO3 (5 mL) and brine (5 mL), then the organic layer was dried over MgSO 4 , filtered, and concentrated.
  • reaction mixture was treated with additional amounts of DBU (0.28 mL, 1.86 mmol, 4 equiv.), perfluoro-1-butanesulfonyl fluoride (0.33 mL, 1.86 mmol, 4 equiv.) and TASF (256 mg, 0.93 mmol, 2 equiv.), then stirred at 40 o C for another 24 h.
  • DBU dimethyl sulfoxide
  • TASF 256 mg, 0.93 mmol, 2 equiv.
  • the disaccharide 4 was obtained as a light yellow powder (300 mg, 60%) along with perfluoro-1-butanesulfonyl compound 7 as a light yellow powder (50 mg, 8%).
  • reaction mixture was directly loaded onto the silica gel column and eluted with acetone/toluene (7:3) as eluent; disaccharide 4 was isolated as a light yellow powder (282 mg, 49%) along with perfluoro-1-butanesulfonyl compound 7 as a light yellow powder (267 mg, 77% brsm).
  • reaction mixture was stirred at 0 o C until TLC indicated the disappearance of starting material (3 hrs).
  • reaction mixture was quenched with Et 3 N (0.25 mL), diluted with EtOAc (25 mL), and filtered through a pad of Celite.
  • the filtrate was washed twice with satd. aq. NaHCO3 (10 mL) and brine (6 mL), and the organic phase was dried over MgSO 4 , filtered, and concentrated.
  • the obtained residue was purified by silica gel column chromatography using acetone/toluene (1:2) as eluent to give compound 14 as a white powder (299 mg, 85%).
  • the reaction mixture was treated sequentially with acceptor 13 (34.2 mg, 0.037 mmol, 1 equiv.), NIS (16.8 mg, 0.075 mmol, 2 equiv.) and TfOH (0.5 M in Et2O, 22.3 ⁇ L, 0.011 mmol, 0.3 equiv.) in anhydrous CH 2 Cl 2 (1.25 mL) with stirring for 10 min under argon.
  • acceptor 13 34.2 mg, 0.037 mmol, 1 equiv.
  • NIS 16.8 mg, 0.075 mmol, 2 equiv.
  • TfOH 0.5 M in Et2O, 22.3 ⁇ L, 0.011 mmol, 0.3 equiv.
  • reaction mixture was quenched with Et3N (0.10 mL), diluted with CH2Cl2 (10 mL), and filtered through a pad of Celite. The filtrate was washed twice with satd. aq. NaHCO 3 (4 mL) and brine (3 mL). The organic phase was dried over MgSO4, filtered, and concentrated. The obtained residue was purified by silica gel column chromatography using acetone/toluene (2:3) as eluent to give compound 16 as a white powder (18.0 mg, 33%) along with the recovered acceptor (12.6 mg, 55% brsm).
  • the product was deacetylated by stirring with NaOMe in MeOH (3 mL, 0.5 M) for 16 h.
  • the reaction mixture was neutralized with IR-120, filtered, and concentrated in vacuo.
  • the residue was purified by LiChroprep ® RP-18 reverse-phase column chromatography using H2O/MeOH (1:4) as eluent.
  • the reaction mixture was filtered through a pad of Celite and concentrated in vacuo.
  • reaction mixture was cooled to -40 °C and treated with NIS (423 mg, 1.88 mmol, 2 equiv.) and TfOH (0.5 M in Et 2 O, 0.47 mL, 0.23 mmol, 0.25 equiv.). After stirring at that temperature for 1.5 h, the TLC analysis indicated disappearance of starting materials and the reaction mixture was quenched with Et 3 N (0.2 mL), and filtered through a pad of Celite. The filtrate was diluted with CH2Cl2 (20 mL), washed with 20% aq. Na 2 S 2 O 3 (5 mL), satd. aq. NaHCO 3 (10 mL) and brine (5 mL).
  • reaction mixture was cooled to 0 °C and NaCNBH3 (313 mg, 4.97 mmol, 10 equiv.) was added, followed by a slow addition of HCl•Et 2 O (2 M in Et 2 O, 2.24 mL, 4.48 mmol, 9 equiv.), and the mixture was continued to stir until TLC indicated the disappearance of starting materials (16 hrs).
  • the reaction mixture was quenched with satd. aq. NaHCO 3 (0.5 mL) and filtered through a pad of Celite. The filtrate was diluted with CH2Cl2 (20 mL) then washed with satd. aq. NaHCO3 (8 mL) and brine (5 mL).
  • reaction mixture was cooled to 0 °C and NaCNBH3 (0.98 g, 15.6 mmol, 10 equiv.) was added, followed by a slow addition of HCl•Et 2 O (2 M in Et 2 O, 7.04 mL, 14.1 mmol, 9 equiv.), and the mixture was stirred until TLC indicated the disappearance of starting materials (16 h).
  • the reaction mixture was quenched with satd. aq. NaHCO3 (0.5 mL) and filtered through a pad of Celite. The filtrate was diluted with CH 2 Cl 2 (50 mL) then washed with satd. aq.
  • the separated organic layer was dried over MgSO 4 , concentrated in vacuo and the obtained residue was used as is for further reactions.
  • the above-obtained residue was added Bu4NOAc (594 mg, 1.97 mmol, 2 equiv.) and dissolved in toluene (18 mL).
  • the solvent was removed in vacuo and the residue was co-evaporated with toluene twice to remove traces of water.
  • the residue was redissolved in anhydrous toluene (12 mL) and the mixture was sonicated for 8 h.
  • the reaction mixture was diluted with EtOAc (20 mL), washed with water (20 mL) and brine (10 mL).
  • the separated organic layer was dried over MgSO 4 and concentrated.
  • Neu5Ac-a2,6-Gal-pNP was synthesized by mixing pNP-b-Gal (1.0 mmol), sialic acid (1.2 mmol), cytidine triphosphate (1.2 mmol), CMP-sialic acid synthetases (CSS, 12 U), pyrophosphatase (PPA, 1U) and a-2,6-sialyltransferase (SiaT, 15U) in 15 mL Tris buffer (pH 7.0) with 5 mM MgCl 2 and 5 mM MnCl 2 .
  • the assays were carried out at 37 o C in duplicates in 96-well plates in a final volume of 50 ⁇ L containing a substrate (0-20 mM), and b-galactosidase (100 mU).
  • the assay conditions for the two sialidases were as follows: C. perfringens (1 mU), sodium acetate buffer (50 mM) pH 5.0 and CaCl 2 (10 mM); V. cholerae (2 mU), sodium acetate buffer (50 mM) pH 5.5, CaCl 2 (10 mM) and NaCl (150 mM). The reactions were carried out for 40 min to 2 hrs for C. perfringens and overnight for V. cholerae.
  • the assays were stopped by adding 65 ⁇ L of CAPS buffer (N-cyclohexyl-3-aminopropane sulfonic acid, 0.5 M, pH 10.5).
  • CAPS buffer N-cyclohexyl-3-aminopropane sulfonic acid, 0.5 M, pH 10.5
  • the amount of the para-nitrophenolate formed was determined by measuring the A405nm of the reaction mixtures using a microplate reader.
  • Three compounds (Neu5Ac-a2,6-GalbpNP, 3F ax -Neu5Ac-a2,6-GalbpNP and 3OH eq -Neu5Ac-a2,6-GalbpNP) were tested as substrates for the enzymes.
  • All three compounds have the background absorbance of A 405nm at 20 mM after incubation for 1 hr at 37 o C in the absence of sialidase.
  • the absorbance of the three compounds Neu5Ac-a2,6-GalbpNP, 3F ax -Neu5Ac-a2,6-GalbpNP and 3OH eq -Neu5Ac-a2,6- GalbpNP were 0.044, 0.129 and 0.072, respectively.
  • the standard curve of pNP was determined by series two-fold dilution of 0.35 mM of pNP, then graphing the A405nm against the concentration of pNP resulted in the standard curve of pNP.
  • the assays were carried out at 37 o C in duplicates in 96-well plates in a final volume of 50 ⁇ L containing the substrate Neu5Ac-a2,6-GalbpNP (0.6 mM), b-galactosidase (100 mU), and sialidase in the absence or presence of an inhibitor at varied concentrations (0-20 mM). Reactions were allowed to proceed for 40 min to 2 hrs for C. perfringens and overnight for V. cholera. The assays were stopped by adding CAPS buffer (65 uL, 0.5 M, pH 10.5). The amount of the para-nitrophenolate formed was determined by measuring the A405nm of the reaction mixture using a microplate reader (FIG.1).
  • EXAMPLE 3 Preparation of Homogeneous mAb Modified with 3F ax -Neu5Ac and Neu5Ac to Study the Effect on Binding to FcgRIIIa by Surface Plasmon Resonance (SPR) Analysis
  • Endo-glycosidases Endo-S, Endo-S2, Endo-S2 mutant (D184Q), and the a-L- fucosidase from Bacteroides fragilis NCTC 9343 were expressed in Escherichia coli and the purification of enzymes was performed using Ni-NTA agarose beads.
  • the column was washed with a Tris-HCl buffer (50 mM, pH 7.4, 20 mL).
  • the bound IgG was released with glycine-HCl (100 mM, pH 3.0, 10 mL), and the elution fractions were immediately neutralized with Tris- HCl buffer (1.0 M, pH 8.3).
  • the fractions containing the antibody were combined and concentrated by centrifugal filtration (Amicon Ultra centrifugal filter, Millipore, Billerica, MA) to give mono-GlcNAc Rituximab (2.4 mg).
  • a glycan oxazoline was added to the mixture of an Endo-S2 D184Q and Mono- GlcNAc Rituximab in 50 mM Tris buffer (pH 7.4). The solution was incubated for 30 min at 37 o C. Then, the reaction mixture was purified with protein-A affinity column, followed by an anion exchange column of Capto Q (GE Healthcare) to collect the desired product.
  • LC-MS/MS experiments were performed on a LTQFT Ultra (linear quadrupole ion trap Fourier transform ion cyclotron resonance) mass spectrometer (Thermo Electron, San Jose, CA) equipped with a nanoelectrospry ion source (New Objective, Inc.), an Agilent 1100 Series binary high-performance liquid chromatography pump (Agilent Technologies, Palo Alto, CA), and a Famos autosampler (LC Packings, San Francisco, CA).
  • the digestion solution (6 mL) was injected at the 10 mL/min flow rate to a self-packed precolumn (150 mm I.D.
  • SPR Surface Plasmon Resonance
  • the RRVs were measured in triplicates by following the experimental procedure reported previously. 34
  • Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells.
  • Sialylglycosides as Selective Inhibitors of Influenza Hemagglutinin and

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2020/014608 2019-04-05 2020-03-10 Sialidase-resistant saccharide and method of making and using the same Ceased WO2020205034A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US17/598,064 US12384811B2 (en) 2019-04-05 2020-03-10 Sialidase-resistant saccharide and method of making and using the same
IL286492A IL286492B1 (en) 2019-04-05 2020-03-10 Sialide-resistant saccharide and its production and use
KR1020267002768A KR20260018203A (ko) 2019-04-05 2020-03-10 시알리다제-내성 당류 및 이의 제조 및 사용 방법
KR1020217031324A KR102920761B1 (ko) 2019-04-05 2020-03-10 시알리다제-내성 당류 및 이의 제조 및 사용 방법
CN202080022413.3A CN115605491B (zh) 2019-04-05 2020-03-10 抗唾液酸酶的糖类、其制造方法及用途
EP20783332.8A EP3947406A4 (en) 2019-04-05 2020-03-10 SIALIDA-RESISTANT SACCHARIDE, AND PROCESSES FOR THE PREPARATION AND USE THEREOF
JP2021558537A JP7621270B2 (ja) 2019-04-05 2020-03-10 シアリダーゼ耐性糖およびその調製および使用方法
CA3131096A CA3131096A1 (en) 2019-04-05 2020-03-10 Sialidase-resistant saccharide and method of making and using the same
JP2025005021A JP2025063181A (ja) 2019-04-05 2025-01-14 シアリダーゼ耐性糖およびその調製および使用方法
US19/267,282 US20260008803A1 (en) 2019-04-05 2025-07-11 Sialidase-resistant saccharide and method of making and using the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962829736P 2019-04-05 2019-04-05
US62/829,736 2019-04-05

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US17/598,064 A-371-Of-International US12384811B2 (en) 2019-04-05 2020-03-10 Sialidase-resistant saccharide and method of making and using the same
US19/267,282 Division US20260008803A1 (en) 2019-04-05 2025-07-11 Sialidase-resistant saccharide and method of making and using the same

Publications (1)

Publication Number Publication Date
WO2020205034A1 true WO2020205034A1 (en) 2020-10-08

Family

ID=72666761

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/014608 Ceased WO2020205034A1 (en) 2019-04-05 2020-03-10 Sialidase-resistant saccharide and method of making and using the same

Country Status (9)

Country Link
US (2) US12384811B2 (https=)
EP (1) EP3947406A4 (https=)
JP (2) JP7621270B2 (https=)
KR (2) KR20260018203A (https=)
CN (1) CN115605491B (https=)
CA (1) CA3131096A1 (https=)
IL (1) IL286492B1 (https=)
TW (1) TWI749504B (https=)
WO (1) WO2020205034A1 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12085340B2 (en) 2016-11-08 2024-09-10 Academia Sinica Recombinant virus, composition comprising the same, and uses thereof
US12157763B2 (en) 2021-10-01 2024-12-03 Academia Sinica Antibody specific to spike protein of SARS-CoV-2 and uses thereof
US12178870B2 (en) 2020-05-08 2024-12-31 Academia Sinica Chimeric influenza vaccines
US12257298B2 (en) 2021-04-12 2025-03-25 Academia Sinica Coronavirus vaccine
US12318485B2 (en) 2023-04-08 2025-06-03 Rock Biomedical, Inc. Methods and compositions for targeted delivery by polymersomes
US12384811B2 (en) 2019-04-05 2025-08-12 Academia Sinica Sialidase-resistant saccharide and method of making and using the same
US12508235B2 (en) 2023-04-08 2025-12-30 Rock Biomedical, Inc. Methods and compositions for dendritic cell targeting nano-delivery
US12545941B2 (en) 2023-05-17 2026-02-10 Rock Biomedical, Inc. MGAT1 deficient cells and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184004A1 (en) * 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0812695A (ja) * 1994-06-30 1996-01-16 Nisshin Oil Mills Ltd:The 新規シアル酸供与体
US7569376B2 (en) 2002-05-03 2009-08-04 Neose Technologies, Inc. Fucosyltransferase fusion protein
CA2441677A1 (en) 2003-05-09 2004-11-09 Adaltis Inc. Peptides and mixtures thereof for detecting antibodies to severe acute respiratory syndrome-associated coronavirus
US20090214590A1 (en) 2005-07-08 2009-08-27 Wayne State University Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
DK3438131T3 (da) 2006-02-10 2022-04-11 Life Technologies Corp Oligosaccharidmodifikation og mærkning af proteiner
PT2170365T (pt) 2007-06-25 2016-07-12 Autoimmune Tech Llc Composições e métodos inibidores de influenza
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US7981428B2 (en) 2008-01-23 2011-07-19 Academia Sinica Flu vaccines and methods of use thereof
RU2011111640A (ru) 2008-08-29 2012-10-10 Симфоген А/С (Dk) Антитела против cd5
CN107375919B (zh) 2009-03-27 2022-07-29 台湾地区“中央研究院” 抗病毒免疫的方法和组合物
HUE039100T2 (hu) 2009-06-24 2018-12-28 Medicago Inc Hemagglutinint tartalmazó kimer influenzavírus-jellegû részecskék
US20130005797A1 (en) 2010-03-18 2013-01-03 Merck Sharp & Dohme Corp. Endosomolytic poly(amidoamine) disulfide polymers for the delivery of oligonucleotides
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
EP2654787A1 (en) 2010-12-22 2013-10-30 Novavax, Inc. Modified influenza hemagglutinin proteins and uses thereof
EP4241785B1 (en) 2011-09-20 2026-01-28 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
WO2013067652A1 (en) 2011-11-10 2013-05-16 Beijing Advaccine Biotechnology Co., Ltd. Facilitator-dna combination vaccine
WO2014055474A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
TW201442721A (zh) * 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
ES2802274T3 (es) 2013-05-02 2021-01-18 Momenta Pharmaceuticals Inc Glicoproteínas sialiladas
WO2015031166A1 (en) 2013-08-26 2015-03-05 Fred Hutchinson Cancer Research Center Compositions and methods for directed immunogen evolution and uses thereof
US9975925B2 (en) 2013-08-28 2018-05-22 Glaxosmithkline Biologicals S.A. Influenza antigens and antibodies
US10421802B2 (en) 2013-10-18 2019-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides
EP3068891A1 (en) 2013-11-13 2016-09-21 Aequus Biopharma Inc. Engineered glycoproteins and uses thereof
CN105934441A (zh) 2013-11-26 2016-09-07 贝勒医学院 新型sars免疫原性组合物
WO2015142671A2 (en) 2014-03-17 2015-09-24 Flugen, Inc. Influenza virus vectors and uses therefor
CN104189897A (zh) 2014-05-21 2014-12-10 深圳先进技术研究院 一种树突状细胞高效负载抗原的制备方法
JP6779887B2 (ja) 2015-01-24 2020-11-04 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 新規なグリカンコンジュゲートおよびその使用方法
WO2016138160A1 (en) 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
WO2017062496A2 (en) 2015-10-05 2017-04-13 University Of Virginia Patent Foundation Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
EP3374504B1 (en) 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
WO2018035387A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
KR101873527B1 (ko) * 2016-09-02 2018-07-02 부산대학교 산학협력단 시알산 유도체를 포함하는 자궁내막증 예방 또는 치료용 조성물
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
CA3056206A1 (en) 2017-03-15 2018-09-20 Polyneuron Pharmaceuticals Ag Glycopolymers sequestering carbohydrate-binding proteins
US20200231633A1 (en) 2017-07-19 2020-07-23 The Regents Of The University Of California MGAT1-Deficient Cells for Production of Vaccines and Biopharmaceutical Products
AU2018312563A1 (en) 2017-08-01 2020-03-12 City Of Hope Anti-IL1RAP antibodies
CN111770991A (zh) 2017-12-18 2020-10-13 通用医疗公司 糖工程
US11191777B2 (en) 2018-06-20 2021-12-07 International Business Machines Corporation Antimicrobial guanidinium macromolecules with bacteria targeting moieties
CA3104297A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CN110713537B (zh) 2018-07-13 2023-04-21 江苏怀瑜药业有限公司 一种sema4d抗体及其制备方法和应用
KR20210061393A (ko) 2018-09-18 2021-05-27 유니버시테이트 젠트 치료용 나노입자 및 이의 사용 방법
WO2020077159A1 (en) 2018-10-10 2020-04-16 The Johns Hopkins University POLY(Beta-AMINO ESTER) NANOPARTICLES FOR THE NON-VIRAL DELIVERY OF PLASMID DNA FOR GENE EDITING AND RETINAL GENE THERAPY
WO2020172072A1 (en) 2019-02-21 2020-08-27 The General Hospital Corporation Glycoengineering immunoglobulin e
WO2020198865A1 (en) 2019-04-03 2020-10-08 The University Of British Columbia Oligopeptides for quantitative viral proteomic analysis methods and uses
US12384811B2 (en) 2019-04-05 2025-08-12 Academia Sinica Sialidase-resistant saccharide and method of making and using the same
GB201908352D0 (en) 2019-06-11 2019-07-24 Innovation Ulster Ltd Sonodynamic therapy
FR3098110B1 (fr) 2019-07-03 2022-02-04 Chanel Parfums Beaute Composition cosmétique solide
BR112022001185A2 (pt) 2019-08-01 2022-03-15 Acm Biolabs Pte Ltd Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos
BR102019017792A2 (pt) 2019-08-27 2021-11-16 Fundação Oswaldo Cruz Receptáculo proteico, método para produção do receptáculo, método de identificação de patógenos ou de diagnóstico de doenças, e, uso do receptáculo
US20220387461A1 (en) 2019-09-04 2022-12-08 Victoria Link Ltd Cancer vaccine
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2021174128A1 (en) 2020-02-26 2021-09-02 University Of Maryland, College Park Compositions and methods for mucosal vaccination against sars-cov-2
MX2022011142A (es) 2020-03-09 2022-12-13 Abcellera Biologics Inc Anticuerpos anti-coronavirus y metodos de uso.
GB202003632D0 (en) 2020-03-12 2020-04-29 Harbour Antibodies Bv SARS-Cov-2 (SARS2, COVID-19) antibodies
IL296426A (en) 2020-03-19 2022-11-01 Baseclick Gmbh Maran"im that underwent a change for the development of a component
KR20250107297A (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
US20210316002A1 (en) 2020-04-14 2021-10-14 Ut-Battelle, Llc Compositions and methods for drug delivery and treating viral infections
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
RU2720614C9 (ru) 2020-04-23 2021-02-09 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Иммунобиологическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
KR20230005962A (ko) 2020-05-01 2023-01-10 니코데 테라퓨틱스 에이에스에이 베타코로나바이러스 예방 및 치료요법
TWI870591B (zh) 2020-05-08 2025-01-21 中央研究院 嵌合流感疫苗
IL298333A (en) 2020-05-20 2023-01-01 Alexandru Adrian Hennrich A viral assembly vector for a vaccine against the corona virus cell
CN116322732A (zh) 2020-06-17 2023-06-23 迪斯拉普申实验室公司 用治疗剂补充产品的组合物及其使用方法
US10906944B2 (en) 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines
RU2730897C1 (ru) 2020-07-01 2020-08-26 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) СПОСОБ ИСПОЛЬЗОВАНИЯ РЕКОМБИНАНТНЫХ БЕЛКОВ SARS-COV-2 В СОСТАВЕ ТЕСТ-СИСТЕМЫ ДЛЯ ИММУНОФЕРМЕНТНОГО АНАЛИЗА С ОПРЕДЕЛЕНИЕМ УРОВНЕЙ АНТИТЕЛ КЛАССОВ IgM, IgG, IgA В СЫВОРОТКЕ/ПЛАЗМЕ КРОВИ БОЛЬНЫХ COVID-19
WO2022047401A1 (en) 2020-08-31 2022-03-03 The University Of Chicago Targeted, intracellular delivery of therapeutic peptides using supramolecular nanomaterials
CN112626124B (zh) 2020-10-15 2023-04-11 广州达博生物制品有限公司 一种病毒保存试剂
BR112023005961A2 (pt) 2021-04-12 2023-10-24 Academia Sinica Molécula de ácido nucleico modificada, vacina combinada, nanopartícula, nanocluster de mrna, método para prevenir ou tratar uma infecção por coronavírus, método para reforço de uma resposta imune adaptativa, peptídeo imunogênico e composição imunogênica
BR112023000666A2 (pt) 2021-04-12 2023-10-24 Academia Sinica Imunógeno, composição imunogênica, método para induzir uma resposta imune contra um coronavírus 2 da síndrome respiratória aguda grave e uso da composição imunogênica
JP2024517711A (ja) 2021-04-29 2024-04-23 ノバルティス アーゲー 高シアル酸付加細胞
CN113265050B (zh) 2021-04-30 2022-08-23 浙江大学 一种可降解高分子材料和自组装纳米复合物及应用
GB202111759D0 (en) 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
US20250195639A1 (en) 2021-10-20 2025-06-19 The Regents Of The University Of California Multi-epitope mrna sars-cov-2 vaccine for boosting immunity through the activation of cd4 and cd8 t cells as well as b lymphocytes
WO2023129928A2 (en) 2021-12-27 2023-07-06 Academia Sinica Antibody specific to spike protein of sars-cov-2 and uses thereof
CN116478948A (zh) 2023-03-01 2023-07-25 中山大学 一种生成高唾液酸化蛋白药物的细胞工程方法
AU2024252371B2 (en) 2023-04-08 2026-02-12 Rock Biomedical Inc. Methods and compositions for dendritic cell targeting nano-delivery
WO2024215616A2 (en) 2023-04-08 2024-10-17 Rock Biomedical Inc. Methods and compositions for dendritic cell targeting vaccines
US12318485B2 (en) 2023-04-08 2025-06-03 Rock Biomedical, Inc. Methods and compositions for targeted delivery by polymersomes
WO2024238734A2 (en) 2023-05-17 2024-11-21 Rock Biomedical Inc. Mgat1 deficient cells and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184004A1 (en) * 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HARSHAL A. CHOKHAWALA, HONGZHI CAO, HAI YU, AND XI CHEN: "Enzymatic Synthesis of Fluorinated Mechanistic Probes for Sialidases and Sialyltransferases", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, US, vol. 129, no. 35, 5 September 2007 (2007-09-05), US, pages 10630 - 10631, XP002632965, ISSN: 0002-7863, DOI: 10.1021/ja072687u *
HAYASHI, T.: "Stereospecific α-Sialylation by Site-Selective Fluorination", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, WILEY, vol. 58, 25 January 2019 (2019-01-25), pages 3814 - 3818, XP055740953 *
HONG-JAY LO, KRASNOVA LARISSA, DEY SUPRIYA, CHENG TING, LIU HAITIAN, TSAI TSUNG-I, WU KEVIN BINCHIA, WU CHUNG-YI, WONG CHI-HUEY: "Synthesis of Sialidase-Resistant Oligosaccharide and Antibody Glycoform Containing α2,6-Linked 3F ax -Neu5Ac", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, US, vol. 141, no. 16, 10 April 2019 (2019-04-10), US, pages 6484 - 6488, XP055623890, ISSN: 0002-7863, DOI: 10.1021/jacs.9b01991 *
KAORU OKAMOTO, TADAO KONDO, TOSHIO GOTO: "An effective synthesis of α-glycosides of N-acetylneuraminic acid derivatives by use of 2-deoxy-2β-halo-3β-hydroxy-4,7,8,9-tetra-O-acetyl- N-acetylneuraminic acid methyl ester", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 43, no. 24, 1 January 1987 (1987-01-01), AMSTERDAM, NL, pages 5919 - 5928, XP055740946, ISSN: 0040-4020, DOI: 10.1016/S0040-4020(01)87797-8 *
See also references of EP3947406A4 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12085340B2 (en) 2016-11-08 2024-09-10 Academia Sinica Recombinant virus, composition comprising the same, and uses thereof
US12607406B2 (en) 2016-11-08 2026-04-21 Academia Sinica Recombinant virus, composition comprising the same, and uses thereof
US12384811B2 (en) 2019-04-05 2025-08-12 Academia Sinica Sialidase-resistant saccharide and method of making and using the same
US12178870B2 (en) 2020-05-08 2024-12-31 Academia Sinica Chimeric influenza vaccines
US12257298B2 (en) 2021-04-12 2025-03-25 Academia Sinica Coronavirus vaccine
US12157763B2 (en) 2021-10-01 2024-12-03 Academia Sinica Antibody specific to spike protein of SARS-CoV-2 and uses thereof
US12318485B2 (en) 2023-04-08 2025-06-03 Rock Biomedical, Inc. Methods and compositions for targeted delivery by polymersomes
US12508235B2 (en) 2023-04-08 2025-12-30 Rock Biomedical, Inc. Methods and compositions for dendritic cell targeting nano-delivery
US12545941B2 (en) 2023-05-17 2026-02-10 Rock Biomedical, Inc. MGAT1 deficient cells and uses thereof

Also Published As

Publication number Publication date
US20220267363A1 (en) 2022-08-25
US12384811B2 (en) 2025-08-12
JP2022529408A (ja) 2022-06-22
IL286492A (en) 2021-12-01
CA3131096A1 (en) 2020-10-08
TW202104272A (zh) 2021-02-01
US20260008803A1 (en) 2026-01-08
KR102920761B1 (ko) 2026-02-02
KR20210137485A (ko) 2021-11-17
EP3947406A1 (en) 2022-02-09
TWI749504B (zh) 2021-12-11
KR20260018203A (ko) 2026-02-06
IL286492B1 (en) 2026-04-01
JP7621270B2 (ja) 2025-01-24
JP2025063181A (ja) 2025-04-15
CN115605491A (zh) 2023-01-13
CN115605491B (zh) 2026-03-24
EP3947406A4 (en) 2022-12-28

Similar Documents

Publication Publication Date Title
US20260008803A1 (en) Sialidase-resistant saccharide and method of making and using the same
Kondo et al. Glycosyl phosphites as glycosylation reagents: scope and mechanism
US10266502B2 (en) Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
CN105308061A (zh) 经同位素标记的聚糖的合成和用途
Chennaiah et al. Conversion of glycals into vicinal-1, 2-diazides and 1, 2-(or 2, 1)-azidoacetates using hypervalent iodine reagents and Me 3 SiN 3. Application in the synthesis of N-glycopeptides, pseudo-trisaccharides and an iminosugar
WO2012135049A1 (en) Compounds and methods for chemical and chemo-enzymatic synthesis of complex glycans
Cattaneo et al. Orthogonal cleavage of the 2-naphthylmethyl group in the presence of the p-methoxy phenyl-protected anomeric position and its use in carbohydrate synthesis
Hribernik et al. One pot synthesis of thio-glycosides via aziridine opening reactions
Swarts et al. Chemical synthesis and functionalization of clickable glycosylphosphatidylinositol anchors
EP4585601A1 (en) Novel oligosaccharide, production intermediate for novel oligosaccharide, production method for novel oligosaccharide, and production method for production intermediate for novel oligosaccharide
EP4424717A1 (en) Novel oligosaccharide, manufacturing intermediate for novel oligosaccharide, and method for manufacturing these
Robina et al. Glycosylation Methods in Oligosaccharide Synthesis. Part 1
WO2022191313A1 (ja) 糖鎖及び糖鎖を含む医薬品の製造方法
JP6198207B2 (ja) 新規糖供与体及びそれを用いた糖鎖の合成方法
Takashio et al. The Structure of Ribocitrin and its Structure-activity Relationship in the Inhibition of Dextransucrase of Streptococcus mutans E49
Likhosherstov et al. Synthesis of N-glycyl-β-glycopyranosyl amines, derivatives of natural oligosaccharides—glucose analogs of Lex antigen
CN106632518B (zh) 一种鬼臼毒素4-oh衍生物的制备方法
Gray et al. Chemical Biology
Yi Remote Anchimeric Assistance for α-Galactosylation Via a Transient [2.2. 3]-Bicyclic Trithiophosphates
HK40109704A (en) Novel oligosaccharide, manufacturing intermediate for novel oligosaccharide, and method for manufacturing these
Wu S nthesis and immunological e aluation of Pel and Psl gl cocon ugate accine candidates against Pseudomonas aeruginosa
EP1097163A4 (en) IMPROVED GLYCOSYLATION PROCESS USING SULFOXIDE DONORS
Auzanneau Christopher J. Moore and France-Isabelle Auzanneau
長﨑 et al. Chemical Synthesis of Core Fucose Containing
Chopra et al. STATEMENT OF CONTRIBUTION TO CO-AUTHORED PAPER (In Communication)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20783332

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3131096

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021558537

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20217031324

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020783332

Country of ref document: EP

Effective date: 20211105

WWG Wipo information: grant in national office

Ref document number: 17598064

Country of ref document: US

WWD Wipo information: divisional of initial pct application

Ref document number: 327130

Country of ref document: IL